PhaseBio jumps after completing trial for drug to reverse blood-thinner effects

PhaseBio Pharmaceuticals

24/09/2019 22:47

** Drug developer's shares  PHAS.O  rise 12.5% to $4.4 after
the closing bell 
    ** Co says it completed a mid-stage trial for its drug to
reverse the blood thinning effects of AstraZeneca's  AZN.L 
heart drug Brilinta  urn:newsml:reuters.com:*:nGNX7CHmYk
    ** PHAS to present full data from the trial at an upcoming
medical congress 
    ** Co says plans to advance the drug into another mid-stage
trial in Q4 and a late-stage trial in Q1 2020 
    ** Stock set to add to its 26.5% YTD gain 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 806749 8325))